Product image of Mivacron (Mivacurium Chloride) supplied by GNH India

Mivacron

Active Ingredient:
Mivacurium Chloride
Origin:
EU

Mivacron (Mivacurium Chloride)

Mivacurium chloride, the active ingredient in Mivacron, is a non‑depolarizing neuromuscular blocking agent presented as an injectable solution for intravenous use. It facilitates endotracheal intubation, provides skeletal muscle relaxation during surgery, and assists ventilation in intensive‑care settings.

GNH India supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with distribution across EU and other regulated markets. The company ensures product quality through stringent quality‑assurance processes and compliance with global regulatory standards.

Manufacturer / TM Owner

Aspen Pharma Trading Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mivacron, a non‑depolarizing neuromuscular blocker, is used in clinical situations that require rapid skeletal muscle relaxation.

  • Facilitation of endotracheal intubation: provides short‑acting muscle relaxation to allow safe airway placement.
  • Skeletal muscle relaxation during surgery: enables controlled paralysis for optimal surgical conditions.
  • Assistance with ventilation in intensive care: supports mechanical ventilation by reducing patient effort.

How It Works

  • Mivacurium chloride acts by competitively antagonizing nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine‑mediated depolarization of the motor end‑plate. This blockade inhibits transmission of nerve impulses to skeletal muscle fibers, resulting in a rapid and reversible loss of muscle tone and paralysis suitable for controlled surgical and intensive‑care procedures.

Side Effects

Mivacron may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Flushing: transient reddening of the skin due to histamine release.
  • Histamine‑related hypotension: mild drop in blood pressure.
  • Tachycardia: temporary increase in heart rate.
  • Bronchospasm: narrowing of the airways, especially in susceptible individuals.
  • Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate intervention.
  • Prolonged paralysis: extended muscle weakness beyond expected duration.
  • Malignant hyperthermia trigger: rare hypermetabolic crisis in susceptible patients.
  • Cardiac arrest: life‑threatening cessation of heart activity.
  • Severe bronchospasm: intense airway constriction leading to respiratory distress.

Precautions & Warnings

When using Mivacron, clinicians should observe several safety measures to minimize risk.

  • Neuromuscular monitoring: assess depth of blockade continuously.
  • Hemodynamic observation: watch for hypotension and tachycardia.
  • Hypersensitivity screening: avoid in patients with known allergy to mivacurium or related compounds.
  • Hepatic/renal impairment: use caution and consider dose adjustment in reduced‑function patients.
  • Elderly patients: initiate with lower doses and titrate carefully.
  • Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mivacron can interact with other agents that influence neuromuscular transmission or cardiovascular stability.

Major Interactions (Avoid)

  • Other neuromuscular blocking agents: additive paralysis.
  • Aminoglycoside antibiotics (e.g., gentamicin): potentiate blockade.
  • Magnesium sulfate: enhances muscle relaxation.
  • Potent cholinesterase inhibitors (e.g., neostigmine in high doses): may reduce effectiveness.
  • Volatile anesthetics at high concentrations: increase risk of hypotension.

Moderate Interactions (Monitor Closely)

  • Calcium channel blockers: may augment hypotensive effect.
  • Beta‑blockers: can mask tachycardia response.
  • Diuretics: potential electrolyte shifts affecting neuromuscular function.
  • Opioids: synergistic respiratory depression.
  • Antihistamines: may alter histamine‑mediated side‑effects.

Frequently Asked Questions

Mivacron is an intravenous neuromuscular blocking agent used to facilitate endotracheal intubation, provide skeletal muscle relaxation during operative procedures, and assist mechanical ventilation in intensive‑care settings where controlled paralysis is required.

Mivacurium chloride competitively blocks nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine‑induced depolarization of skeletal muscle fibers. This inhibition stops nerve‑muscle transmission, producing a rapid and reversible loss of muscle tone.

The dose of Mivacron is individualized by the prescribing clinician based on patient weight, clinical context, and desired depth of blockade. Dosing guidelines are provided in the product label, but the final regimen is determined by the treating physician.

Mivacron’s pregnancy category is listed as unknown. It should only be used during pregnancy or lactation when the potential benefit justifies any possible risk to the fetus or infant, and after careful evaluation by the healthcare provider.

To request Mivacron, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Mivacron is a short‑acting, non‑depolarizing blocker that is metabolized by plasma cholinesterases, leading to a rapid offset of action. Compared with agents like rocuronium, which have longer durations and are eliminated hepatically, Mivacron offers quicker recovery but may cause more histamine‑related effects.

Mivacron should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain stability.

Mivacron is administered as an intravenous injection. The drug is supplied as a sterile injectable solution that is drawn into a syringe and given as a bolus dose, followed by additional dosing if required, under continuous neuromuscular monitoring.

Serious risks include anaphylactic reactions, prolonged neuromuscular paralysis, malignant hyperthermia in susceptible individuals, severe bronchospasm, and cardiovascular collapse such as cardiac arrest. Immediate recognition and supportive measures are essential if these events occur.

Mivacron is contraindicated in patients with known hypersensitivity to mivacurium or any component of the formulation. Caution is also advised for individuals with severe hepatic or renal impairment, a history of malignant hyperthermia, or uncontrolled asthma due to the risk of bronchospasm.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mivacurium Chloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT